GR1008017B - Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης - Google Patents

Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης

Info

Publication number
GR1008017B
GR1008017B GR20120100410A GR20120100410A GR1008017B GR 1008017 B GR1008017 B GR 1008017B GR 20120100410 A GR20120100410 A GR 20120100410A GR 20120100410 A GR20120100410 A GR 20120100410A GR 1008017 B GR1008017 B GR 1008017B
Authority
GR
Greece
Prior art keywords
levothyroxine
preparation
pharmaceutically acceptable
acceptable salt
drinkable solution
Prior art date
Application number
GR20120100410A
Other languages
English (en)
Inventor
Χρηστος Κωνσταντινου Κουτσοδημος
Γεωργιος Δημητριου Μοτσιος
Original Assignee
Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων, filed Critical Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων,
Priority to GR20120100410A priority Critical patent/GR1008017B/el
Priority to EP13386023.9A priority patent/EP2692340B1/en
Publication of GR1008017B publication Critical patent/GR1008017B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ένα σταθερό φαρμακευτικό σύστημα (κιτ) για την παρασκευή πόσιμου διαλύματος λεβοθυροξίνης ή φαρμακευτικώς αποδεκτού άλατος αυτής, το οποίο αποτελείται από ένα στερεό προς ανασύσταση υπό μορφή κόνεων ή κόκκων και από ένα υγρό ανασύστασης. Το στερεό προς ανασύσταση περιέχει επίσης τουλάχιστον ένα έκδοχο - φορέα της δραστικής, κατά προτίμηση υδατοδιαλυτό, ακόμα προτιμότερα σορβιτόλη ή μαλτοδεξτρίνη ή μείγμα αυτών. Το υγρό ανασύστασης είναι υδατικό και περιέχει τουλάχιστον ένα έκδοχο για τη διάλυση της δραστικής ουσίας, κατά προτίμηση πολυβινυλοπυρρολιδόνη και προαιρετικά τουλάχιστον ένα συντηρητικό.
GR20120100410A 2012-08-03 2012-08-03 Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης GR1008017B (el)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20120100410A GR1008017B (el) 2012-08-03 2012-08-03 Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης
EP13386023.9A EP2692340B1 (en) 2012-08-03 2013-07-29 Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20120100410A GR1008017B (el) 2012-08-03 2012-08-03 Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης

Publications (1)

Publication Number Publication Date
GR1008017B true GR1008017B (el) 2013-10-24

Family

ID=49223709

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20120100410A GR1008017B (el) 2012-08-03 2012-08-03 Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης

Country Status (2)

Country Link
EP (1) EP2692340B1 (el)
GR (1) GR1008017B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297677B1 (en) * 2015-05-19 2023-07-12 Altergon S.a. Liquid pharmaceutical formulations of tetraiodothyronine
NL2017110B1 (en) 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
US20200046664A1 (en) * 2016-10-10 2020-02-13 Ftf Pharma Private Limited Method for preparation of liquid oral composition of l-thyroxin
CN116421557A (zh) * 2023-06-02 2023-07-14 泊诺(天津)创新医药研究有限公司 一种左甲状腺素钠口服液的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225204A (en) 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
GB9401891D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5635209A (en) 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
GR20100100508A (el) * 2010-09-10 2012-04-30 Alapis Α.Β.Ε.Ε., Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου

Also Published As

Publication number Publication date
EP2692340B1 (en) 2015-03-11
EP2692340A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
MY189913A (en) Preparation containing tetracyclic compound at high dose
MX2013007057A (es) Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.
SG10201804817TA (en) Delayed release compositions of linaclotide
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
IL233200A0 (en) The history of alpha-boronic acid, its preparation and pharmaceutical preparations containing it
EA201691322A1 (ru) Фармацевтическая композиция ингибитора dpp-iv в комбинации с метформином
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MX2013001677A (es) Formulaciones estables de linaclotida.
EA201300053A1 (ru) Фосфатсвязывающий препарат для удобного приема
WO2013068565A3 (en) Melatonin-based solutions and powders for their preparation
PH12015500823A1 (en) Modified release formulations for oprozomib
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
GR1008017B (el) Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης
EP2743275A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A HONEY CHERRY EXTRACT AND ANTIBIOTICS, PHARMACEUTICAL KIT, AND USE OF A HONEY CHERRY EXTRACT FOR THE MANUFACTURE OF MEDICAMENTS
MY173564A (en) Cxcr7 receptor modulators
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
PH12015501301A1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
TN2016000207A1 (en) Pharmaceutical dosage forms.
EP2567710A4 (en) AQUEOUS PHARMACEUTICAL SYSTEM FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES ON THE NAILS
IL223752A (en) Perindopril's Arginine Salt Crystalline Delta Form, a process for making it and its pharmaceutical preparations
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
HK1208171A1 (en) Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20131118